Innate immune signal transduction specificity in inflammatory disease

炎症性疾病中的先天免疫信号转导特异性

基本信息

  • 批准号:
    8126597
  • 负责人:
  • 金额:
    $ 7.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The innate immune system recognizes and responds to pathogenic organisms. In doing so, this system is responsible for initiating a cytokine response designed to tailor the adaptive immune system to eradicate the offending organism. This process must be tightly regulated as too much activity can lead to inflammatory disease. Because inflammatory diseases are characterized by prolonged innate immune activation and cytokine release, the mechanisms controlling downregulation of the innate immune response are paramount in limiting inflammatory pathology. This grant application aims to study the mechanisms of this downregulation by focusing on the signal transduction mechanisms of NOD2 protein (CARD15 gene) and on NOD2's role in initiating and maintaining the cytokine response. The NOD2 protein is responsible for a number of inflammatory disorders including Blau Syndrome (a familial granulomatosis disease), a subset of Early Onset Sarcoidosis and for 15-20% of genetic Crohn's Disease. NOD2 is activated in response to intracellular exposure to both gram-positive and gram-negative bacteria after which it helps to coordinate NF-?B activation and cytokine release through the lysine-63 (K63)-linked polyubiquitination of a novel site (K285) on the IKK scaffolding protein NEMO. We have recently extended this finding to show that the major extracellular innate immune signaling receptors, the Toll-like Receptors (TLRs), also require K285 NEMO ubiquitination to properly signal through NF-?B. This work suggests that regulation of the post-translational modifications on the IKK scaffolding protein, NEMO, helps to coordinate cross-talk between intracellular and extracellular innate immune pathways and also helps to regulate the identity, the amount and the duration of cytokines that are released. These findings also suggest that for NF-?B signaling, multiple innate immune signaling pathways converge on NEMO and that the post-translational modifications on NEMO serve as a rheostat to control NF-?B activity. As such, these post-translational modifications may also be targets for molecules aimed at downregulating the NF-?B response activated by NOD2 and other innate immune signaling pathways. The central hypothesis of this grant is that downregulation of NOD2 and TLR-stimulated NF-?B activation is paramount in avoiding inflammatory pathology. Failure to properly downregulate the NF-?B response and coordinate between alternative (MAP kinase) signaling pathways may underlie the pathophysiology of inflammatory disorders. Study of these pathways of downregulation could lead both to novel insight regarding the pathophysiology of these diseases and to novel druggable target to help treat these diseases. To begin to tackle this important problem, we have generated significant preliminary data. We have identified a novel innate immune-induced phosphorylation site on NEMO that controls NEMO ubiquitination and therefore, controls ultimate NF-?B activation. We have also identified a signaling pathway operating through an unexpected MAP3K which inhibits NEMO ubiquitination and shifts innate immune signaling from NF-?B activity toward p38 activity. The Specific Aims of this grant application aim to determine the biochemical mechanisms by which innate immune-induced NF-?B activity can be downregulated, to determine the function of MEKK4 in dictating signal specificity downstream of innate immune system activation and to determine the role of these signaling pathways in the pathophysiology of inflammatory disease. Public Health Relevance: As humans, we are constantly exposed to bacteria, fungi and viruses, and we must respond to these pathogens so that we do not become infected. After responding to these pathogens, if our immune systems do not deactivate, we develop inflammatory disorders such as asthma, inflammatory bowel disease, multiple sclerosis and atherosclerosis (heart and vascular disease). Inflammatory diseases such as these are a significant cause of morbidity and mortality across a wide range of populations (infants to elderly). Due to the importance of downregulating the inflammatory response, our bodies have developed sophisticated mechanisms to dampen the inflammatory response. This grant application aims to study the mechanisms that dampen this inflammatory response and the mechanisms by which this dampening is faulty in inflammatory disease. This work aims to help determine the causes of inflammatory disease and aims to identify novel targets for pharmaceutical intervention in these debilitating disorders.
描述(由申请人提供):先天免疫系统识别病原生物并对其做出反应。在此过程中,该系统负责启动细胞因子反应,旨在调整适应性免疫系统以根除有害生物体。这一过程必须受到严格监管,因为过多的活动可能导致炎症性疾病。由于炎症性疾病的特点是延长先天免疫激活和细胞因子释放,因此控制先天免疫反应下调的机制对于限制炎症病理至关重要。本次拨款申请旨在通过关注 NOD2 蛋白(CARD15 基因)的信号转导机制以及 NOD2 在启动和维持细胞因子反应中的作用来研究这种下调的机制。 NOD2 蛋白导致许多炎症性疾病,包括布劳综合征(一种家族性肉芽肿病)、早发性结节病的一个亚型以及 15-20% 的遗传性克罗恩病。 NOD2 在细胞内接触革兰氏阳性和革兰氏阴性细菌时被激活,之后它通过 IKK 支架蛋白 NEMO 上新位点 (K285) 的赖氨酸 63 (K63) 连接的多泛素化帮助协调 NF-κB 激活和细胞因子释放。我们最近扩展了这一发现,表明主要的细胞外先天免疫信号受体,Toll 样受体 (TLR),也需要 K285 NEMO 泛素化才能通过 NF-κB 正确发出信号。这项工作表明,调节 IKK 支架蛋白 NEMO 的翻译后修饰有助于协调细胞内和细胞外先天免疫途径之间的串扰,还有助于调节释放的细胞因子的身份、数量和持续时间。这些发现还表明,对于 NF-κB 信号传导,多种先天免疫信号传导途径在 NEMO 上汇聚,并且 NEMO 上的翻译后修饰可充当控制 NF-κB 活性的变阻器。因此,这些翻译后修饰也可能是旨在下调 NOD2 和其他先天免疫信号传导途径激活的 NF-κB 反应的分子的靶标。该资助的中心假设是 NOD2 和 TLR 刺激的 NF-κB 激活的下调对于避免炎症病理学至关重要。未能正确下调 NF-κB 反应以及替代(MAP 激酶)信号传导途径之间的协调可能是炎症性疾病病理生理学的基础。对这些下调途径的研究可以带来关于这些疾病的病理生理学的新见解,以及帮助治疗这些疾病的新的药物靶标。为了开始解决这个重要问题,我们已经生成了重要的初步数据。我们在 NEMO 上发现了一个新的先天免疫诱导的磷酸化位点,该位点控制 NEMO 泛素化,从而控制最终的 NF-κB 激活。我们还发现了一条通过意想不到的 MAP3K 起作用的信号通路,该通路抑制 NEMO 泛素化并将先天免疫信号从 NF-κB 活性转变为 p38 活性。本次拨款申请的具体目的是确定下调先天免疫诱导的 NF-κB 活性的生化机制,确定 MEKK4 在决定先天免疫系统激活下游信号特异性中的功能,并确定这些信号通路在炎症性疾病病理生理学中的作用。 公共卫生相关性:作为人类,我们不断接触细菌、真菌和病毒,我们必须对这些病原体做出反应,以免被感染。在对这些病原体作出反应后,如果我们的免疫系统没有失活,我们就会患上炎症性疾病,如哮喘、炎症性肠病、多发性硬化症和动脉粥样硬化(心脏和血管疾病)。诸如此类的炎症性疾病是广泛人群(婴儿到老年人)发病和死亡的重要原因。由于下调炎症反应的重要性,我们的身体已经发展出复杂的机制来抑制炎症反应。这项拨款申请旨在研究抑制这种炎症反应的机制以及这种抑制在炎症性疾病中出现故障的机制。这项工作旨在帮助确定炎症性疾病的原因,并确定药物干预这些衰弱性疾病的新靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Derek W Abbott其他文献

Derek W Abbott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Derek W Abbott', 18)}}的其他基金

Innate Immune signal transduction specificity in inflammatory disease
炎症性疾病中的先天免疫信号转导特异性
  • 批准号:
    10201055
  • 财政年份:
    2021
  • 资助金额:
    $ 7.14万
  • 项目类别:
Innate Immune signal transduction specificity in inflammatory disease
炎症性疾病中的先天免疫信号转导特异性
  • 批准号:
    10398950
  • 财政年份:
    2021
  • 资助金额:
    $ 7.14万
  • 项目类别:
Cellular Engineering to identify gasdermin protein networks regulating inflammatory cell death
细胞工程鉴定调节炎症细胞死亡的gasdermin蛋白网络
  • 批准号:
    10654565
  • 财政年份:
    2020
  • 资助金额:
    $ 7.14万
  • 项目类别:
Cellular Engineering to identify gasdermin protein networks regulating inflammatory cell death
细胞工程鉴定调节炎症细胞死亡的gasdermin蛋白网络
  • 批准号:
    10024452
  • 财政年份:
    2020
  • 资助金额:
    $ 7.14万
  • 项目类别:
Cellular Engineering to identify gasdermin protein networks regulating inflammatory cell death
细胞工程鉴定调节炎症细胞死亡的gasdermin蛋白网络
  • 批准号:
    10441354
  • 财政年份:
    2020
  • 资助金额:
    $ 7.14万
  • 项目类别:
Cellular Engineering to identify gasdermin protein networks regulating inflammatory cell death
细胞工程鉴定调节炎症细胞死亡的gasdermin蛋白网络
  • 批准号:
    10223156
  • 财政年份:
    2020
  • 资助金额:
    $ 7.14万
  • 项目类别:
Glycome-Enhanced KnockOut (GEKO) Technology
糖类增强敲除 (GEKO) 技术
  • 批准号:
    9108958
  • 财政年份:
    2015
  • 资助金额:
    $ 7.14万
  • 项目类别:
Glycome-Enhanced KnockOut (GEKO) Technology
糖类增强敲除 (GEKO) 技术
  • 批准号:
    8985066
  • 财政年份:
    2015
  • 资助金额:
    $ 7.14万
  • 项目类别:
The Role of NEMO Ubiquitination in EDA-ID
NEMO 泛素化在 EDA-ID 中的作用
  • 批准号:
    8227941
  • 财政年份:
    2011
  • 资助金额:
    $ 7.14万
  • 项目类别:
The Role of NEMO Ubiquitination in EDA-ID
NEMO 泛素化在 EDA-ID 中的作用
  • 批准号:
    8113808
  • 财政年份:
    2011
  • 资助金额:
    $ 7.14万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 7.14万
  • 项目类别:
    Studentship
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
    Operating Grants
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
    Salary Programs
Mechanistic Study of Inspiratory Training in Childhood Asthma
儿童哮喘吸气训练机制研究
  • 批准号:
    10637048
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 7.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了